Incyte Corp Drug Patent Portfolio

Incyte Corp's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Incyte Corp News

Exploring Incyte: The Impact of a Targeted Biotech Pipeline on the Future of Cancer Treatment and...

03 Jan, 2026

European Commission Greenlights Incyte's Minjuvi Combination Treatment for Relapsed Cases ... - GeneOnline

18 Dec, 2025

Incyte abandons its BET inhibitor and anti-CD122 medication - Fierce Biotech

28 Oct, 2025

FDA Alert: Updates on Merck, Sanofi, Biogen, and Others - BioSpace

15 Sep, 2025

See More